- Home
- OGI vs TLSI Comparison
OGI vs TLSI Comparison
Compare OGI & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGI
- TLSI
- Stock Information
- Founded
- OGI 2013
- TLSI 2010
- Country
- OGI Canada
- TLSI United States
- Employees
- OGI N/A
- TLSI N/A
- Industry
- OGI Biotechnology: Pharmaceutical Preparations
- TLSI Medical Specialities
- Sector
- OGI Health Care
- TLSI Health Care
- Exchange
- OGI Nasdaq
- TLSI Nasdaq
- Market Cap
- OGI 200.6M
- TLSI 124.9M
- IPO Year
- OGI N/A
- TLSI N/A
- Fundamental
- Price
- OGI $1.53
- TLSI $4.69
- Analyst Decision
- OGI
- TLSI Strong Buy
- Analyst Count
- OGI 0
- TLSI 6
- Target Price
- OGI N/A
- TLSI $11.75
- AVG Volume (30 Days)
- OGI 820.8K
- TLSI 36.4K
- Earning Date
- OGI 02-11-2025
- TLSI 11-14-2024
- Dividend Yield
- OGI N/A
- TLSI N/A
- EPS Growth
- OGI N/A
- TLSI N/A
- EPS
- OGI N/A
- TLSI N/A
- Revenue
- OGI $118,317,480.00
- TLSI $26,891,000.00
- Revenue This Year
- OGI $57.65
- TLSI $60.96
- Revenue Next Year
- OGI $10.93
- TLSI $53.65
- P/E Ratio
- OGI N/A
- TLSI N/A
- Revenue Growth
- OGI 0.69
- TLSI 67.90
- 52 Week Low
- OGI $1.31
- TLSI $3.50
- 52 Week High
- OGI $2.91
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- OGI 44.32
- TLSI 51.68
- Support Level
- OGI $1.56
- TLSI $4.72
- Resistance Level
- OGI $1.77
- TLSI $5.32
- Average True Range (ATR)
- OGI 0.08
- TLSI 0.31
- MACD
- OGI -0.00
- TLSI 0.01
- Stochastic Oscillator
- OGI 11.11
- TLSI 47.52
About OGI Organigram Holdings Inc.
OrganiGram Holdings Inc is engaged in producing indoor-grown cannabis for patients and adult recreational consumers in Canada. The company has also developed a portfolio of adult-use recreational cannabis brands including Edison, Big Bag o' Buds, SHRED, Monjour, Holy Mountain, and Trailblazer. Tremblant Cannabis, and artisanal craft brand, Laurentian are recent additions to Organigram's existing brand portfolio.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.